EU/3/12/1008: Orphan designation for the treatment of sickle cell disease

Human erythrocytes encapsulating inositol hexaphosphate


On 4 July 2012, orphan designation (EU/3/12/1008) was granted by the European Commission to ERYtech Pharma, France, for human erythrocytes encapsulating inositol hexaphosphate for the treatment of sickle cell disease.

Key facts

Active substance
Human erythrocytes encapsulating inositol hexaphosphate
Intended use
Treatment of sickle cell disease
Orphan designation status
EU designation number
Date of designation
ERYtech Pharma S.A.
Batiment Adenine
60 Avenue Rockefeller
69008 Lyon
Telephone: +33 4 78 74 44 38
Telefax: +33 4 78 75 56 29

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating